Key Insights

Highlights

Success Rate

84% trial completion

Published Results

59 trials with published results (28%)

Research Maturity

117 completed trials (56% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

11.1%

23 terminated out of 208 trials

Success Rate

83.6%

-2.9% vs benchmark

Late-Stage Pipeline

22%

45 trials in Phase 3/4

Results Transparency

50%

59 of 117 completed with results

Key Signals

59 with results84% success23 terminated

Data Visualizations

Phase Distribution

149Total
Not Applicable (33)
Early P 1 (1)
P 1 (15)
P 2 (55)
P 3 (30)
P 4 (15)

Trial Status

Completed117
Recruiting27
Terminated23
Unknown17
Active Not Recruiting12
Not Yet Recruiting6

Trial Success Rate

83.6%

Benchmark: 86.5%

Based on 117 completed trials

Clinical Trials (208)

Showing 20 of 20 trials
NCT07470879Phase 2RecruitingPrimary

A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

NCT05076175Phase 2RecruitingPrimary

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

NCT07012395Phase 2Recruiting

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT05668013Phase 2Active Not Recruiting

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT04779307Phase 3CompletedPrimary

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

NCT05156125Phase 2TerminatedPrimary

VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT06398626RecruitingPrimary

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

NCT06867094Phase 2RecruitingPrimary

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

NCT05588843Phase 2Active Not RecruitingPrimary

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

NCT04647578Completed

Physical Fitness Levels in Children and Adolescents With Chronic Inflammatory Bowel Disease (CIBD): Crohn's Disease, Ulcerative Colitis, Chronic Unclassified Colitis

NCT07463183Phase 2RecruitingPrimary

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

NCT07296315Phase 2RecruitingPrimary

Confirmatory Clinical Study in Active Ulcerative Colitis

NCT07532213Not Yet Recruiting

A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab

NCT07196748Phase 3RecruitingPrimary

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Phase 2Active Not RecruitingPrimary

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07302360RecruitingPrimary

A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis

NCT05528510Phase 3Active Not RecruitingPrimary

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05092269Phase 3Active Not Recruiting

A Long-term Extension Study of Ustekinumab in Pediatric Participants

NCT06663332Phase 3Recruiting

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT07242248Recruiting

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

Scroll to load more

Research Network

Activity Timeline